 |
|
|
| |
A novel liver-directed locked nucleic acid targeting PD-L1 expression reverts HBV-specific immune tolerance and induces sustained clearance of HBV infection
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
JieZhao2, LykkePedersen3, Julie Blaising1, Malika Ait-Goughoulte1, Fang Shen2, YoujunYu2, Johanna Walther1,Anna-Maria Geretti1, Timothy Tellinghuisen1, John AT Young1, SørenOttosen3and Souphalone Luangsay1
1Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland 2Roche Innovation Center Shanghai, Shanghai, China 3Roche Innovation Center Copenhagen, Hørsholm, Denmark
|
| |
|
|
|
|
|
